Dyslipidemia

A review of REDUCE-IT data prior to an FDA supplemental new drug application decision shows the unprecedented benefit of the fish oil therapy.

Amarin announced the FDA had granted their sNDA for icosapent ethyl to reduce residual CV risk in patients with statin-managed LDL-C cholesterol.

MAASTRICHT, The Netherlands--The significant combined effect of bempedoic acid and ezetimibe on LDL-C in patients at high risk for CV events may suggest a new era of non-statin therapy. 

MAASTRICHT, The Netherlands-Study results suggest that clinical trials of novel treatments targeting Lp(a) will not be affected by subjects with CV disease receiving antiplatelet therapy.

Data from ACC 2018 showed the PCSK9 inhibitor is associated with an absolute risk reduction of 1.6% in treated patients versus placebo.

About 4 million Americans can’t tolerate statins. A new study suggests bempedoic acid could be used to help these patients lower their LDL cholesterol.

In 2018, the American College of Cardiology and American Heart Association teamed up to update treatment guidelines for atherosclerotic cardiovascular disease. Learn more in this recap.

The application to the FDA for icosapent ethyl seeks a new indication to reduce the risk of major adverse cardiovascular events.

A study of patients recommended for statin therapy under ACC/AHA guidelines, but not taking any, found that 59.2% reported never being offered a statin.

A new cohort assessment shows white and African American men both have a lifetime hypertension risk of more than 80%.

It's been 4 years since the drug class reached the market. Are patients adhering to the therapy, and what more potential does it have?

A new long-term data analysis reports that about 50% of patients adhere to the critcal therapy after just 1 year, and the rate continues to drop after that.

Atrial fibrillation patients at risk for acute coronary syndrome, stroke and blood clots have better outcomes with an antithrombotic regimen of apixaban without aspirin, researchers report.

Recently new therapy options are becoming more evidenced by the day. But have they reached their fullest potential?

Physicians found bempedoic acid was capable of reducing LDL-C by another 18% without muscle or liver issues due to high-dose statin regimen.

Rodriguez discusses her team's recent 300,000-patient cohort analysis on statin adherence, plus advice on managing at-risk patients with ASCVD.

A 300,000-plus patient cohort analysis showed patients with atherosclerotic cardiovascular disease are at a significantly greater risk of death if they don't adhere to statin prescriptions.

Results of an open label study on omega-3 PUFA supplementation found a small but transient effect on gut microbiota that could warrant future research.

Eliot A. Brinton, MD, outlines the continued unmet needs for patients with familial chylomicronemia syndrome (FCS).

Coronary artery disease remains the top killer of Americans—these tools may help identify people who are still at risk.

Once one of the country healthcare system's greatest successes, CVD and related mortality is rising again. What's its true cause?

Among lipid clinic patients, actual EPA+DHA supplement intake was <50% of prescribed dosage, according to the first study to look at the association.

The seemingly complicated maneuvers of getting patient’s cholesterol better can be resolved with common sense. What’s best for the patient?

Since the PCSK9 inhibitors were approved for cholesterol management by the FDA in 2015, they have been frequently compared.

Wiviott, senior investigator of the DECLARE-TIMI 58 trial, says that SGLT2 inhibitors and GLP-1 receptor agonists are changing the paradigm of how clinicians manage diabetes and cardiovascular risk.